Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Hyperlipidemia
- Sponsor
- University of Manitoba
- Enrollment
- 71
- Locations
- 2
- Primary Endpoint
- Serum Lipids
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The substantial range of individual responsiveness to plant sterols has important ramifications. Marked differences across individuals in particular aspects of the cholesterol metabolic pathway must alter the impact of plant sterol consumption. As such, a pronounced need exists to understand the genetic and metabolic factors that explain the substantial degree of heterogeneity in response of lipid concentrations to plant sterols across individuals. The primary focus of this trial is to delineate the impact of differing cholesterol synthesis levels on response of LDL-C and other plasma lipids to plant sterol consumption. Participants pre-identified as high or low endogenous cholesterol synthesizers, according to their screening level of lathosterol to cholesterol ratios, will be given PS or a placebo containing margarine to consume under supervision for 4 weeks in a crossover design. The trial will characterize the responsiveness of the participants' total, LDL, and HDL cholesterol, as well as triacylglycerol (TG) concentrations, to plant sterol consumption. This research will determine if cholesterol synthesis phenotype predicts the responsiveness of lipids to plant sterol consumption. Variations in candidate genes involved in cholesterol metabolism will also be investigated in order to find associations with both cholesterol metabolism phenotypes and responsiveness of lipids to plant sterols. The output of this research will be to advance the knowledge of which genetic factors influence the degree of cardiovascular benefit derived from plant sterols through lipid lowering.
Investigators
Dr. Peter J. H. Jones
Professor, Food Science and Human Nutritional Sciences
University of Manitoba
Eligibility Criteria
Inclusion Criteria
- •fasting serum LDL cholesterol \>3.0 mmol/L
- •high or low lathosterol to cholesterol ratio
Exclusion Criteria
- •use of lipid lowering therapy
- •documented cardiovascular/atherosclerotic disease
- •inflammatory disease
- •uncontrolled hypertension
- •kidney disease
- •liver disease
- •other systemic diseases
- •chronic alcohol consumption (\> 2 servings/day)
Outcomes
Primary Outcomes
Serum Lipids
Time Frame: Baseline (Day 1,2) and Endpoint (Day 27,28) of each experimental period
Total Cholesterol, LDL-C, HDL-C, Triglycerides
Serum non-cholesterol sterols
Time Frame: Baseline (Day 1,2) and Endpoint (Day 27,28) of each experimental period
Lathosterol,Lanosterol,Desmosterol,Sitosterol,Campesterol,Cholestanol,
Genotype via single nucleotide polymorphism analysis
Time Frame: Baseline
SNP genotyping in genes related to cholesterol metabolism
Secondary Outcomes
- Cholesterol synthesis measurement by deuterium incorporation(Endpoint (Day 27,28) of each experimental period)
- Change in cholesterol absorption due to plant sterol consumption(Change in cholesterol absorption from control period (measured over days 24-28) to plant sterol period (days 24-28))